Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;43(4):1277-1285.
doi: 10.1007/s10067-024-06868-w. Epub 2024 Feb 14.

Development of a novel clinimetric tool: PAtient Reported Disease Activity Index in Rheumatoid Arthritis (PARDAI-RA) by PANLAR, for the assessment of patients living with rheumatoid arthritis

Daniel G Fernández-Ávila  1 , Daniela Patiño-Hernández  2 , Socorro Moreno-Luna  3 , Lorena Brance  4 , Álvaro Arbeláez  5 , Antonio Cachafeiro Vilar  6 , Carlos Lozada  7 , Carlos Ríos  8 , Carlos Toro  9 , Claudia Ramírez  10 , Guillermo Pons-Estel  11 , Manuel Ugarte-Gil  12 , María Narváez  10 , Miguel Albanese  13 , Orlando Roa  10 , Oscar Ruiz  10 , Paula Burgos  14 , Ricardo Xavier  15 , Yurilis Fuentes  16 , Enrique Soriano  17
Affiliations

Development of a novel clinimetric tool: PAtient Reported Disease Activity Index in Rheumatoid Arthritis (PARDAI-RA) by PANLAR, for the assessment of patients living with rheumatoid arthritis

Daniel G Fernández-Ávila et al. Clin Rheumatol. 2024 Apr.

Abstract

Background: Clinical experience has shown that a single measure is not sufficient to assess disease activity in rheumatoid arthritis (RA). Various clinimetric tools are necessary to address the many clinical situations that can arise.

Methods: In order to develop a comprehensive measurement tool, the Pan American League of Associations for Rheumatology searched for the most frequent measures of disease activity applied in RA by means of a semi-systematic review of the available literature.

Results: We found that the most frequently reported measures of disease activity were the 28-joint Disease Activity Score, C-reactive protein, and the erythrocyte sedimentation rate, followed by patient-reported measures of pain and stiffness and many other composite indices and patient-reported outcome measures. The most frequent physician-reported sign of disease was the swollen joint count, and the most frequently self-reported feature was the increase in disease activity or flares.

Conclusion: In this article, we present a new clinimetric tool developed based on expert consensus and on data retrieved from our search. Disease activity can be better assessed by combining various data sources, such as clinical, laboratory, and self-reported outcomes. These variables were included in our novel clinimetric tool. Key Points • The goal of treatment of RA is to achieve the best possible control of inflammation, or even remission; therefore, disease management should include systematic and regular evaluation of inflammation and health status. • Clinimetric tools evaluate a series of variables (e.g., symptoms, functional capacity, disease severity, quality of life, disease progression) and can reveal substantial prognostic and therapeutic differences between patients. • Our clinimetric tool, which is based on a combination of data (e.g., clinical variables, laboratory results, PROMs), can play a relevant role in patient assessment and care.

Keywords: Assessment; Clinimetrics; Management; Patient-reported outcome measures; Rheumatoid arthritis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Screening process. Based on: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71
Fig. 2
Fig. 2
Proposed clinimetric tool for rheumatoid arthritis. PARDAI-RA by PANLAR
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591–602. doi: 10.1038/s41584-022-00827-y. - DOI - PubMed
    1. Scott IC, Whittle R, Bailey J, Twohig H, Hider SL, Mallen CD, Muller S, Jordan KP. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data. Lancet Reg Health Eur. 2022;23:100519. doi: 10.1016/j.lanepe.2022.100519. - DOI - PMC - PubMed
    1. van Delft ETAM, Jamal M, den Braanker H, Kuijper TM, Hazes JMW, Lopes Barreto D, Weel-Koenders AEAM. A systematic review on time trend incidence of rheumatoid arthritis in outpatient rheumatology clinics. Front Med (Lausanne) 2022;9:933884. doi: 10.3389/fmed.2022.933884. - DOI - PMC - PubMed
    1. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. doi: 10.1007/s00296-020-04731-0. - DOI - PubMed
    1. Fernández-Ávila DG, Rincón-Riaño DN, Bernal-Macías S, Gutiérrez Dávila JM, Rosselli D. Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. Rev Colomb Reumatol. 2019;26:83–87. - PubMed

MeSH terms

Substances